^
Association details:
| Biomarker: | KIT exon 18 mutation |
|---|---|
| Cancer: | Gastrointestinal Stromal Tumor |
| Drug: | Qinlock (ripretinib) (c-KIT inhibitor, FLT3 inhibitor, PDGFR α inhibitor) |
| Direction: | Sensitive |
Evidence:
Title:
Deciphera Pharmaceuticals Announces Results from ctDNA Analysis from INTRIGUE Phase 3 Clinical Study Demonstrating Substantial Clinical Benefit of QINLOCK® in Second-Line GIST Patients with Mutations in KIT Exon 11 and 17/18 Only
Published date:
01/03/2023
Excerpt:
Deciphera Pharmaceuticals, Inc...announced findings of a planned exploratory analysis of data from the INTRIGUE Phase 3 clinical study of QINLOCK using circulating tumor DNA (ctDNA) from a subgroup of patients with gastrointestinal stromal tumor (GIST) previously treated with imatinib who harbor mutations in KIT exon 11 and 17/18 only..Patients with mutations in KIT exon 11 and exon 17/18 only had substantially improved progression-free survival (PFS), objective response rate (ORR), and overall survival (OS) with QINLOCK versus sunitinib.
Trial ID:
Source:
Title:
The efficacy and safety of ripretinib in Chinese patients with advanced gastrointestinal stromal tumors: A multicenter, retrospective study.
Published date:
01/17/2023
Excerpt:
Patients with KIT exon 17/18 mutation had a longer PFS (hazard ratio, 0.097; 95% CI, 0.011 to 0.871; P = 0.037)….Ripretinib can provide clinical benefit in advanced GIST in real-world China with a favorable safety profile.
DOI:
10.1200/JCO.2023.41.3_suppl.800
